Literature DB >> 19598005

Methyltetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy.

Kubilay Ukinc1, Halil Onder Ersoz, Caner Karahan, Cihangir Erem, Selcuk Eminagaoglu, Arif Bayram Hacihasanoglu, Mustafa Yilmaz, Mustafa Kocak.   

Abstract

Hyperhomocysteinemia is a well-defined risk factor for endothelial dysfunction and atherosclerosis. A point mutation (677 C-T) of MTHFR gene results in a significant increase at plasma homocysteine levels. In this study we aimed to evaluate the effects of MTHFR gene mutation and consequent hyperhomocysteinemia on the development of diabetic microvascular complications in comparison with the other defined risk factors. Diabetic patients without a history of macrovascular complication or overt nephropathy enrolled into the study. The presence of MTHFR 677 C-T point mutation was evaluated by Real-Time PCR technique by using a LightCycler. MTHFR heterozygous mutation was present in 24 patients over 52. Patients with diabetes were divided into two groups according to the presence of MTHFR gene mutation. Both groups were well matched regarding age and diabetes duration. Metabolic parameters, plasma homocysteine, microalbuminuria, folic acid, and vitamin B12 levels were also studied. Presence of neuropathy and retinopathy were evaluated by specific tests. Duration of diabetes, BMI, systolic and diastolic blood pressure, plasma CRP, HbA1c, and lipid levels were not different between the two groups. Plasma homocysteine (12.89 +/- 1.74 and 8.98 +/- 1.91 micromol/l; P < 0.0001) and microalbuminuria levels (73.40 +/- 98.15 and 29.53 +/- 5.08 mg/day; P = 0.021) were significantly higher in the group with MTHFR gene mutation while creatinine clearance levels (101.1 +/- 42.6 and 136.21 +/- 51.50 ml/min; P = 0.008) were significantly lower. Sixteen over 22 (73%) of the patients with diabetic nephropathy had MTHFR gene mutation, while this was only 27% (8 over 30) in normoalbuminuric patients (P = 0.017). There was a significant correlation of plasma homocysteine level with microalbuminuria (r = 0.54; P = 0.031) in the patients with diabetic nephropathy who had C677T polymorphism. We did not find any specific association of MTHFR gene mutation and hyperhomocysteinemia with retinopathy or neuropathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19598005     DOI: 10.1007/s12020-009-9218-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  24 in total

Review 1.  Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis.

Authors:  V Fonseca; S C Guba; L M Fink
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

2.  Plasma homocysteine and its determinants in diabetic retinopathy.

Authors:  O Vaccaro; A F Perna; F P Mancini; V Cuomo; M Sacco; A Tufano; A A Rivellese; D Ingrosso; G Riccardi
Journal:  Diabetes Care       Date:  2000-07       Impact factor: 19.112

3.  Standards of medical care in diabetes--2008.

Authors: 
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

4.  Thermolabile methylenetetrahydrofolate reductase enzyme genotype is frequent in type 2 diabetic patients with normal fasting homocysteine levels.

Authors:  N B Tutuncu; T Erbas; M Alikasifoglu; E Tuncbilek
Journal:  J Intern Med       Date:  2005-05       Impact factor: 8.989

5.  Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study.

Authors:  M A Gall; P Hougaard; K Borch-Johnsen; H H Parving
Journal:  BMJ       Date:  1997-03-15

6.  Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase.

Authors:  S S Kang; J Zhou; P W Wong; J Kowalisyn; G Strokosch
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

7.  Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy.

Authors:  Dariusz Moczulski; Hanna Fojcik; Ewa Zukowska-Szczechowska; Ilona Szydlowska; Wladyslaw Grzeszczak
Journal:  Nephrol Dial Transplant       Date:  2003-08       Impact factor: 5.992

8.  Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.

Authors:  M Ravid; R Lang; R Rachmani; M Lishner
Journal:  Arch Intern Med       Date:  1996-02-12

9.  Is diabetic nephropathy an inherited complication?

Authors:  K Borch-Johnsen; K Nørgaard; E Hommel; E R Mathiesen; J S Jensen; T Deckert; H H Parving
Journal:  Kidney Int       Date:  1992-04       Impact factor: 10.612

10.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.

Authors:  P F Jacques; A G Bostom; R R Williams; R C Ellison; J H Eckfeldt; I H Rosenberg; J Selhub; R Rozen
Journal:  Circulation       Date:  1996-01-01       Impact factor: 29.690

View more
  17 in total

1.  Ethnogeographic prevalence and implications of the 677C>T and 1298A>C MTHFR polymorphisms in US primary care populations.

Authors:  James S Graydon; Karla Claudio; Seth Baker; Mohan Kocherla; Mark Ferreira; Abiel Roche-Lima; Jovaniel Rodríguez-Maldonado; Jorge Duconge; Gualberto Ruaño
Journal:  Biomark Med       Date:  2019-06-03       Impact factor: 2.851

2.  MTHFR gene C677T polymorphism and type 2 diabetic nephropathy in Asian populations: a meta-analysis.

Authors:  Haiyan Chen; Fang Wei; Lihua Wang; Zhe Wang; Jia Meng; Lan Jia; Guijiang Sun; Ruining Zhang; Bo Li; Haibo Yu; Haiyan Pang; Xueqing Bi; Hongye Dong; Aili Jiang; Lin Wang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 3.  The genetics of vascular complications in diabetes mellitus.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

Review 4.  Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control.

Authors:  J R Miranda-Massari; M J Gonzalez; F J Jimenez; M Z Allende-Vigo; J Duconge
Journal:  Curr Clin Pharmacol       Date:  2011-11

5.  Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathy.

Authors:  Francisco J Jiménez-Ramírez; Liza M Castro; Clarymar Ortiz; Jennifer Concepción; Jessicca Y Renta; Raúl H Morales-Borges; Jorge R Miranda-Massari; Jorge Duconge
Journal:  Drug Metab Pers Ther       Date:  2017-03-01

6.  Effects of Common Polymorphisms in the MTHFR and ACE Genes on Diabetic Peripheral Neuropathy Progression: a Meta-Analysis.

Authors:  Shuai Wu; Yan Han; Qiang Hu; Xiaojie Zhang; Guangcheng Cui; Zezhi Li; Yangtai Guan
Journal:  Mol Neurobiol       Date:  2016-03-12       Impact factor: 5.590

7.  NMDA Receptors as Potential Therapeutic Targets in Diabetic Nephropathy: Increased Renal NMDA Receptor Subunit Expression in Akita Mice and Reduced Nephropathy Following Sustained Treatment With Memantine or MK-801.

Authors:  Hila Roshanravan; Eun Young Kim; Stuart E Dryer
Journal:  Diabetes       Date:  2016-07-07       Impact factor: 9.461

Review 8.  Vitamins and type 2 diabetes mellitus.

Authors:  Roxana Valdés-Ramos; Ana Laura Guadarrama-López; Beatriz Elina Martínez-Carrillo; Alejandra Donají Benítez-Arciniega
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2015       Impact factor: 2.895

Review 9.  Methylenetetrahydrofolate reductase gene polymorphism and risk of type 2 diabetes mellitus.

Authors:  Jian-Hong Zhong; A Chapin Rodríguez; Na-Na Yang; Le-Qun Li
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

10.  N-Methyl-D-aspartate receptor activation, novel mechanism of homocysteine-induced blood-retinal barrier dysfunction.

Authors:  Amany Tawfik; Riyaz Mohamed; Dina Kira; Suhib Alhusban; Mohamed Al-Shabrawey
Journal:  J Mol Med (Berl)       Date:  2020-11-06       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.